Evernest Financial Advisors LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Evernest Financial Advisors LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 14.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 9,024 shares of the company’s stock after purchasing an additional 1,163 shares during the quarter. Evernest Financial Advisors LLC’s holdings in Johnson & Johnson were worth $1,497,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of JNJ. Ironwood Investment Counsel LLC lifted its position in Johnson & Johnson by 1.5% during the first quarter. Ironwood Investment Counsel LLC now owns 62,114 shares of the company’s stock valued at $10,301,000 after purchasing an additional 937 shares during the last quarter. CenterBook Partners LP increased its stake in Johnson & Johnson by 9.1% in the first quarter. CenterBook Partners LP now owns 41,680 shares of the company’s stock valued at $6,912,000 after acquiring an additional 3,465 shares during the last quarter. Keynote Financial Services LLC lifted its stake in Johnson & Johnson by 3.3% during the first quarter. Keynote Financial Services LLC now owns 12,522 shares of the company’s stock worth $2,077,000 after purchasing an additional 400 shares during the last quarter. Headlands Technologies LLC boosted its holdings in shares of Johnson & Johnson by 82.2% in the 1st quarter. Headlands Technologies LLC now owns 31,135 shares of the company’s stock worth $5,163,000 after purchasing an additional 14,051 shares in the last quarter. Finally, Altfest L J & Co. Inc. increased its position in shares of Johnson & Johnson by 4.9% during the 1st quarter. Altfest L J & Co. Inc. now owns 13,838 shares of the company’s stock valued at $2,295,000 after purchasing an additional 646 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.0%

Shares of NYSE JNJ opened at $170.72 on Thursday. The firm’s 50 day moving average price is $158.53 and its 200-day moving average price is $157.10. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $172.18. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market cap of $411.14 billion, a PE ratio of 18.26, a P/E/G ratio of 2.17 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.82 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on JNJ. Guggenheim reaffirmed a “neutral” rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Finally, Raymond James Financial lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.